Louisville, CO, United States of America

Michael Evans


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 54(Granted Patents)


Company Filing History:


Years Active: 2007-2012

Loading Chart...
2 patents (USPTO):Explore Patents

Title: **Michael Evans: Innovator in Cancer Treatment Technologies**

Introduction

Michael Evans, an inventive mind based in Louisville, Colorado, has made significant contributions to the field of cancer treatment through his innovative approach and extensive research. With a total of two patents to his name, Evans continues to push the boundaries of medical science.

Latest Patents

Michael Evans' latest patents focus on materials and methods to potentiate cancer treatment. His work includes compounds that inhibit DNA-dependent protein kinase, compositions comprising these compounds, methods to inhibit DNA-PK biological activity, and methods aimed at sensitizing cells to agents that cause DNA lesions. These advancements are significant in enhancing cancer therapies, providing new avenues for effective treatments.

Career Highlights

Throughout his career, Michael Evans has worked with leading organizations that shape the pharmaceutical landscape. Notable companies include Icos Corporation and Luitpold Pharmaceuticals Inc., where he has contributed to research and development efforts that aim to improve patient outcomes.

Collaborations

Evans has collaborated with esteemed professionals in the field, including James W. Halbrook and Edward A. Kesicki. These partnerships have further enriched his research endeavors, resulting in innovative solutions that address critical challenges in cancer treatment.

Conclusion

Michael Evans stands out as a resourceful inventor dedicated to enhancing cancer treatments through his patents and professional contributions. His work exemplifies the vital role that innovation plays in the ongoing battle against cancer, offering hope for new and improved therapies. As he continues to explore the potential of cancer treatment technologies, the medical community and patients alike can look forward to his future contributions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…